Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Kala Pharmaceuticals to host conference call » 07:55
09/17/20
09/17
07:55
09/17/20
07:55
KALA

Kala Pharmaceuticals

$8.61 /

+0.56 (+6.96%)

Management holds a Key…

Management holds a Key Opinion Leader conference call with Dr. Holland, Director of Cornea Services at Cincinnati Eye Institute, who discusses the unmet need in dry eye disease and the potential for EYSUVIS as a short-term treatment on September 17 at 8 am. Webcast Link

ShowHide Related Items >><<
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

  • 11
    Mar
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

Conference/Events
Kala Pharmaceuticals to host conference call » 04:55
09/17/20
09/17
04:55
09/17/20
04:55
KALA

Kala Pharmaceuticals

$8.61 /

+0.56 (+6.96%)

Management holds a Key…

Management holds a Key Opinion Leader conference call with Dr. Holland, Director of Cornea Services at Cincinnati Eye Institute, who discusses the unmet need in dry eye disease and the potential for EYSUVIS as a short-term treatment on September 17 at 8 am. Webcast Link

ShowHide Related Items >><<
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

  • 11
    Mar
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/17/20
09/17
04:55
09/17/20
04:55
ACRS

Aclaris Therapeutics

$2.40 /

+0.05 (+2.13%)

, AUTL

Autolus Therapeutics

$14.03 /

+0.25 (+1.81%)

, EIGR

Eiger BioPharmaceuticals

$10.07 /

+0.13 (+1.31%)

, INO

Inovio

$18.52 /

+4.89 (+35.88%)

, KALA

Kala Pharmaceuticals

$8.61 /

+0.56 (+6.96%)

, OVID

Ovid Therapeutics

$6.61 /

+0.2 (+3.12%)

, PAVM

PAVmed

$1.89 /

+0.01 (+0.53%)

, SLGL

Sol-Gel Technologies

$7.69 /

+0.22 (+2.95%)

, VNRX

VolitionRx

$3.20 /

+0.015 (+0.47%)

, XFOR

X4 Pharmaceuticals

$7.31 /

+0.25 (+3.54%)

, XNCR

Xencor

$41.53 /

+0.66 (+1.61%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$18.52 /

+4.89 (+35.88%)

XNCR Xencor
$41.53 /

+0.66 (+1.61%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/16/20
09/16
04:55
09/16/20
04:55
ACRS

Aclaris Therapeutics

$2.35 /

+0.135 (+6.09%)

, AUTL

Autolus Therapeutics

$13.78 /

-0.01 (-0.07%)

, EIGR

Eiger BioPharmaceuticals

$9.93 /

-0.21 (-2.07%)

, INO

Inovio

$13.63 /

+2.3 (+20.30%)

, KALA

Kala Pharmaceuticals

$8.04 /

+0.05 (+0.63%)

, OVID

Ovid Therapeutics

$6.41 /

+0.17 (+2.72%)

, PAVM

PAVmed

$1.88 /

+0.055 (+3.01%)

, SLGL

Sol-Gel Technologies

$7.47 /

+0.02 (+0.27%)

, VNRX

VolitionRx

$3.18 /

-0.05 (-1.55%)

, XFOR

X4 Pharmaceuticals

$7.09 /

-0.05 (-0.70%)

, XNCR

Xencor

$40.87 /

+0.66 (+1.64%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$13.63 /

+2.3 (+20.30%)

XNCR Xencor
$40.87 /

+0.66 (+1.64%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 08:33
09/15/20
09/15
08:33
09/15/20
08:33
ACRS

Aclaris Therapeutics

$2.25 /

+0.08 (+3.69%)

, AUTL

Autolus Therapeutics

$13.81 /

+1.15 (+9.08%)

, EIGR

Eiger BioPharmaceuticals

$10.11 /

+0.06 (+0.60%)

, INO

Inovio

$11.33 /

+1.235 (+12.23%)

, KALA

Kala Pharmaceuticals

$7.99 /

-0.77 (-8.79%)

, OVID

Ovid Therapeutics

$6.24 /

+0.54 (+9.47%)

, PAVM

PAVmed

$1.83 /

+0.025 (+1.39%)

, SLGL

Sol-Gel Technologies

$7.45 /

-0.03 (-0.40%)

, VNRX

VolitionRx

$3.21 /

+0.06 (+1.90%)

, XFOR

X4 Pharmaceuticals

$7.14 /

-0.81 (-10.19%)

, XNCR

Xencor

$40.21 /

+2.11 (+5.54%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$11.33 /

+1.235 (+12.23%)

XNCR Xencor
$40.21 /

+2.11 (+5.54%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:24
09/14/20
09/14
16:24
09/14/20
16:24
MSFT

Microsoft

$205.30 /

+1.07 (+0.52%)

, ORCL

Oracle

$59.45 /

+2.445 (+4.29%)

, WMT

Walmart

$137.31 /

+0.62 (+0.45%)

, NVDA

Nvidia

$514.93 /

+28.09 (+5.77%)

, SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, GILD

Gilead

$66.33 /

+1.43 (+2.20%)

, IMMU

Immunomedics

$83.59 /

+41.32 (+97.75%)

, SGEN

Seattle Genetics

$171.96 /

+22.23 (+14.85%)

, MRK

Merck

$84.18 /

+0.93 (+1.12%)

, DIS

Disney

$131.35 /

-0.42 (-0.32%)

, CZR

Caesars

$55.41 /

+5.28 (+10.53%)

, DKNG

DraftKings

$48.60 /

+7.19 (+17.36%)

, AZN

AstraZeneca

$54.02 /

+0.3 (+0.56%)

, PFE

Pfizer

$37.01 /

+0.94 (+2.61%)

, BNTX

BioNTech

$67.48 /

+2.32 (+3.56%)

, SGMS

Scientific Games

$26.44 /

+7.5 (+39.60%)

, VXRT

Vaxart

$7.77 /

+2.48 (+46.88%)

, KALA

Kala Pharmaceuticals

$7.99 /

-0.77 (-8.79%)

, KR

Kroger

$32.83 /

-1.53 (-4.45%)

Stocks gained to start…

ShowHide Related Items >><<
WMT Walmart
$137.31 /

+0.62 (+0.45%)

VXRT Vaxart
$7.77 /

+2.48 (+46.88%)

SGMS Scientific Games
$26.44 /

+7.5 (+39.60%)

SGEN Seattle Genetics
$171.96 /

+22.23 (+14.85%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.01 /

+0.94 (+2.61%)

ORCL Oracle
$59.45 /

+2.445 (+4.29%)

NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

MRK Merck
$84.18 /

+0.93 (+1.12%)

KR Kroger
$32.83 /

-1.53 (-4.45%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

GILD Gilead
$66.33 /

+1.43 (+2.20%)

DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

DIS Disney
$131.35 /

-0.42 (-0.32%)

CZR Caesars
$55.41 /

+5.28 (+10.53%)

BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

09/09/20 DA Davidson
Public-cloud slowing down, Microsoft competition increasing, says DA Davidson
09/09/20 Morgan Stanley
Morgan Stanley sees potential for 10%+ increase in Microsoft dividend
09/09/20 Mizuho
Slack Technologies price target lowered to $25 from $29 at Mizuho
09/08/20 Goldman Sachs
Goldman sticks with Sell on Apple despite 71% rally since downgrade
ORCL Oracle
$59.45 /

+2.445 (+4.29%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$137.31 /

+0.62 (+0.45%)

09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
09/02/20 Jefferies
Jefferies positive on Walmart+ subscription offering following official launch
NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

09/15/20 Needham
Nvidia price target raised to $700 from $600 at Needham
09/15/20 Craig-Hallum
Nvidia price target raised to $500 from $480 at Craig-Hallum
09/15/20 Oppenheimer
Nvidia's acquisition of ARM strengthens AI hand, says Oppenheimer
09/15/20 Citi
Citi lays out five reasons to favor of Nvidia's ARM acquisition
SFTBY SoftBank
$0.00 /

+ (+0.00%)

09/14/20 Deutsche Bank
ARM customers could push back on Nvidia deal, says Deutsche Bank
09/14/20 RBC Capital
RBC Capital sees ARM Holdings deal as positive for Nvidia, negative for Intel
GILD Gilead
$66.33 /

+1.43 (+2.20%)

09/15/20 Maxim
Gilead upgraded to Buy at Maxim following Immunomedics deal
09/15/20 Maxim
Gilead upgraded to Buy from Hold at Maxim
09/15/20 RBC Capital
Gilead price target lowered to $82 from $84 at RBC Capital
09/15/20 Jefferies
Immunomedics downgraded to Hold from Buy at Jefferies
IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
SGEN Seattle Genetics
$171.96 /

+22.23 (+14.85%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/15/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
MRK Merck
$84.18 /

+0.93 (+1.12%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
DIS Disney
$131.35 /

-0.42 (-0.32%)

09/14/20 Jefferies
ESPN deal positive for both Caesars and DraftKings, says Jefferies
09/14/20 Evercore ISI
ESPN deal could add up to material dollars for DraftKings, says Evercore
09/08/20
Fly Intel: Top five analyst upgrades
09/08/20 Deutsche Bank
Disney upgraded to Buy from Hold at Deutsche Bank
CZR Caesars
$55.41 /

+5.28 (+10.53%)

09/14/20 Jefferies
William Hill shares haven't priced in building U.S. momentum, says Jefferies
09/14/20
Fly Intel: Top five analyst initiations
DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

09/15/20 Craig-Hallum
DraftKings price target raised to $60 from $48 at Craig-Hallum
09/15/20 Benchmark
DraftKings price target raised to $57 from $45 at Benchmark
09/15/20 Oppenheimer
DraftKings price target raised to $55 from $50 at Oppenheimer
AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
09/08/20 Cantor Fitzgerald
Cantor Fitzgerald starts 'underappreciated' Entasis at Overweight
PFE Pfizer
$37.01 /

+0.94 (+2.61%)

09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
09/09/20 JMP Securities
Trillium Therapeutics price target raised to $14 from $10 at JMP Securities
09/08/20 B. Riley FBR
Novavax selloff brings 'compelling' buying opportunity, says B. Riley FBR
BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

09/04/20 SVB Leerink
SVB Leerink positive on BioNTech's adding fifth COVID-19 vaccine trial
08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
SGMS Scientific Games
$26.44 /

+7.5 (+39.60%)

08/31/20 Jefferies
After recent filing, Jefferies says 'something happening' at Scientific Games
08/12/20 Craig-Hallum
NJ sports betting up, iGaming revenue still strong, says Craig-Hallum
07/27/20 Deutsche Bank
Scientific Games price target raised to $16 from $8 at Deutsche Bank
06/18/20 Truist
Scientific Games price target raised to $30 from $15 at SunTrust
VXRT Vaxart
$7.77 /

+2.48 (+46.88%)

09/09/20 B. Riley FBR
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
08/12/20 H.C. Wainwright
Vaxart price target raised to $17 from $7 at H.C. Wainwright
07/28/20 B. Riley FBR
Vaxart selloff on NY Times article unwarranted, says B. Riley FBR
07/13/20
Fly Intel: Top five analyst initiations
KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
KR Kroger
$32.83 /

-1.53 (-4.45%)

09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
08/06/20 Credit Suisse
Kroger assumed with a Neutral at Credit Suisse
WMT Walmart
$137.31 /

+0.62 (+0.45%)

SGMS Scientific Games
$26.44 /

+7.5 (+39.60%)

SGEN Seattle Genetics
$171.96 /

+22.23 (+14.85%)

PFE Pfizer
$37.01 /

+0.94 (+2.61%)

ORCL Oracle
$59.45 /

+2.445 (+4.29%)

NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

MRK Merck
$84.18 /

+0.93 (+1.12%)

KR Kroger
$32.83 /

-1.53 (-4.45%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

GILD Gilead
$66.33 /

+1.43 (+2.20%)

DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

DIS Disney
$131.35 /

-0.42 (-0.32%)

CZR Caesars
$55.41 /

+5.28 (+10.53%)

BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

  • 23
    Jul
  • 19
    Jun
  • 29
    Apr
  • 11
    Mar
  • 06
    Feb
  • 05
    Dec
  • 10
    Oct
WMT Walmart
$137.31 /

+0.62 (+0.45%)

VXRT Vaxart
$7.77 /

+2.48 (+46.88%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.01 /

+0.94 (+2.61%)

ORCL Oracle
$59.45 /

+2.445 (+4.29%)

NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

MRK Merck
$84.18 /

+0.93 (+1.12%)

KR Kroger
$32.83 /

-1.53 (-4.45%)

IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

GILD Gilead
$66.33 /

+1.43 (+2.20%)

DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

DIS Disney
$131.35 /

-0.42 (-0.32%)

CZR Caesars
$55.41 /

+5.28 (+10.53%)

BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

VXRT Vaxart
$7.77 /

+2.48 (+46.88%)

SGMS Scientific Games
$26.44 /

+7.5 (+39.60%)

SGEN Seattle Genetics
$171.96 /

+22.23 (+14.85%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.01 /

+0.94 (+2.61%)

NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

MRK Merck
$84.18 /

+0.93 (+1.12%)

KR Kroger
$32.83 /

-1.53 (-4.45%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

GILD Gilead
$66.33 /

+1.43 (+2.20%)

DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

DIS Disney
$131.35 /

-0.42 (-0.32%)

CZR Caesars
$55.41 /

+5.28 (+10.53%)

BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

WMT Walmart
$137.31 /

+0.62 (+0.45%)

VXRT Vaxart
$7.77 /

+2.48 (+46.88%)

SGMS Scientific Games
$26.44 /

+7.5 (+39.60%)

PFE Pfizer
$37.01 /

+0.94 (+2.61%)

ORCL Oracle
$59.45 /

+2.445 (+4.29%)

NVDA Nvidia
$514.93 /

+28.09 (+5.77%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

MRK Merck
$84.18 /

+0.93 (+1.12%)

KR Kroger
$32.83 /

-1.53 (-4.45%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

IMMU Immunomedics
$83.59 /

+41.32 (+97.75%)

GILD Gilead
$66.33 /

+1.43 (+2.20%)

DKNG DraftKings
$48.60 /

+7.19 (+17.36%)

DIS Disney
$131.35 /

-0.42 (-0.32%)

CZR Caesars
$55.41 /

+5.28 (+10.53%)

BNTX BioNTech
$67.48 /

+2.32 (+3.56%)

AZN AstraZeneca
$54.02 /

+0.3 (+0.56%)

MSFT Microsoft
$205.30 /

+1.07 (+0.52%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:03
09/14/20
09/14
12:03
09/14/20
12:03
ORCL

Oracle

$59.92 /

+2.91 (+5.10%)

, MSFT

Microsoft

$208.02 /

+3.79 (+1.86%)

, WMT

Walmart

$138.04 /

+1.35 (+0.99%)

, NVDA

Nvidia

$515.90 /

+29.06 (+5.97%)

, GILD

Gilead

$66.87 /

+1.965 (+3.03%)

, IMMU

Immunomedics

$84.79 /

+42.52 (+100.59%)

, SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$54.13 /

+0.41 (+0.76%)

, SGMS

Scientific Games

$27.62 /

+8.68 (+45.83%)

, VXRT

Vaxart

$7.38 /

+2.09 (+39.51%)

, KALA

Kala Pharmaceuticals

$7.70 /

-1.06 (-12.10%)

, KR

Kroger

$33.23 /

-1.13 (-3.29%)

, PFE

Pfizer

$37.00 /

+0.93 (+2.58%)

, BNTX

BioNTech

$69.00 /

+3.84 (+5.89%)

The major averages are…

ShowHide Related Items >><<
WMT Walmart
$138.04 /

+1.35 (+0.99%)

VXRT Vaxart
$7.38 /

+2.09 (+39.51%)

SGMS Scientific Games
$27.62 /

+8.68 (+45.83%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.00 /

+0.93 (+2.58%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

KR Kroger
$33.23 /

-1.13 (-3.29%)

KALA Kala Pharmaceuticals
$7.70 /

-1.06 (-12.10%)

IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

GILD Gilead
$66.87 /

+1.965 (+3.03%)

BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
09/11/20 Morgan Stanley
Oracle price target raised to $62 from $58 at Morgan Stanley
MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

09/09/20 DA Davidson
Public-cloud slowing down, Microsoft competition increasing, says DA Davidson
09/09/20 Morgan Stanley
Morgan Stanley sees potential for 10%+ increase in Microsoft dividend
09/09/20 Mizuho
Slack Technologies price target lowered to $25 from $29 at Mizuho
09/08/20 Goldman Sachs
Goldman sticks with Sell on Apple despite 71% rally since downgrade
WMT Walmart
$138.04 /

+1.35 (+0.99%)

09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
09/02/20 Jefferies
Jefferies positive on Walmart+ subscription offering following official launch
NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

09/14/20 Jefferies
Nvidia price target raised to $680 after 'transformative' ARM deal at Jefferies
09/14/20 Wedbush
Nvidia's ARM deal viewed favorably at Wedbush
09/14/20 Deutsche Bank
ARM customers could push back on Nvidia deal, says Deutsche Bank
09/14/20 RBC Capital
RBC Capital sees ARM Holdings deal as positive for Nvidia, negative for Intel
GILD Gilead
$66.87 /

+1.965 (+3.03%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
09/14/20 Cantor Fitzgerald
Gilead's Immunomedics deal a step toward oncology future, says Cantor Fitzgerald
09/14/20 H.C. Wainwright
Immunomedics downgraded to Neutral from Buy at H.C. Wainwright
09/14/20 Wells Fargo
Immunomedics downgraded to Equal Weight from Overweight at Wells Fargo
IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

08/20/20 Craig-Hallum
Nvidia price target raised to $480 from $335 at Craig-Hallum
07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
09/08/20 Cantor Fitzgerald
Cantor Fitzgerald starts 'underappreciated' Entasis at Overweight
SGMS Scientific Games
$27.62 /

+8.68 (+45.83%)

08/31/20 Jefferies
After recent filing, Jefferies says 'something happening' at Scientific Games
08/12/20 Craig-Hallum
NJ sports betting up, iGaming revenue still strong, says Craig-Hallum
07/27/20 Deutsche Bank
Scientific Games price target raised to $16 from $8 at Deutsche Bank
06/18/20 Truist
Scientific Games price target raised to $30 from $15 at SunTrust
VXRT Vaxart
$7.38 /

+2.09 (+39.51%)

09/09/20 B. Riley FBR
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
08/12/20 H.C. Wainwright
Vaxart price target raised to $17 from $7 at H.C. Wainwright
07/28/20 B. Riley FBR
Vaxart selloff on NY Times article unwarranted, says B. Riley FBR
07/13/20
Fly Intel: Top five analyst initiations
KALA Kala Pharmaceuticals
$7.70 /

-1.06 (-12.10%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
KR Kroger
$33.23 /

-1.13 (-3.29%)

09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
08/06/20 Credit Suisse
Kroger assumed with a Neutral at Credit Suisse
PFE Pfizer
$37.00 /

+0.93 (+2.58%)

09/09/20 JMP Securities
Trillium Therapeutics price target raised to $14 from $10 at JMP Securities
09/08/20 B. Riley FBR
Novavax selloff brings 'compelling' buying opportunity, says B. Riley FBR
08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

09/04/20 SVB Leerink
SVB Leerink positive on BioNTech's adding fifth COVID-19 vaccine trial
WMT Walmart
$138.04 /

+1.35 (+0.99%)

SGMS Scientific Games
$27.62 /

+8.68 (+45.83%)

PFE Pfizer
$37.00 /

+0.93 (+2.58%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

KR Kroger
$33.23 /

-1.13 (-3.29%)

KALA Kala Pharmaceuticals
$7.70 /

-1.06 (-12.10%)

IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

GILD Gilead
$66.87 /

+1.965 (+3.03%)

BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

  • 23
    Jul
  • 29
    Apr
  • 11
    Mar
  • 06
    Feb
  • 05
    Dec
  • 10
    Oct
WMT Walmart
$138.04 /

+1.35 (+0.99%)

VXRT Vaxart
$7.38 /

+2.09 (+39.51%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.00 /

+0.93 (+2.58%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

KR Kroger
$33.23 /

-1.13 (-3.29%)

IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

GILD Gilead
$66.87 /

+1.965 (+3.03%)

BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

VXRT Vaxart
$7.38 /

+2.09 (+39.51%)

SGMS Scientific Games
$27.62 /

+8.68 (+45.83%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

PFE Pfizer
$37.00 /

+0.93 (+2.58%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

KR Kroger
$33.23 /

-1.13 (-3.29%)

KALA Kala Pharmaceuticals
$7.70 /

-1.06 (-12.10%)

IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

GILD Gilead
$66.87 /

+1.965 (+3.03%)

BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

WMT Walmart
$138.04 /

+1.35 (+0.99%)

VXRT Vaxart
$7.38 /

+2.09 (+39.51%)

SGMS Scientific Games
$27.62 /

+8.68 (+45.83%)

PFE Pfizer
$37.00 /

+0.93 (+2.58%)

ORCL Oracle
$59.92 /

+2.91 (+5.10%)

NVDA Nvidia
$515.90 /

+29.06 (+5.97%)

MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

KR Kroger
$33.23 /

-1.13 (-3.29%)

KALA Kala Pharmaceuticals
$7.70 /

-1.06 (-12.10%)

IMMU Immunomedics
$84.79 /

+42.52 (+100.59%)

GILD Gilead
$66.87 /

+1.965 (+3.03%)

BNTX BioNTech
$69.00 /

+3.84 (+5.89%)

AZN AstraZeneca
$54.13 /

+0.41 (+0.76%)

MSFT Microsoft
$208.02 /

+3.79 (+1.86%)

Downgrade
Fly Intel: Top five analyst downgrades » 10:15
09/14/20
09/14
10:15
09/14/20
10:15
JAZZ

Jazz Pharmaceuticals

$139.02 /

+2.1 (+1.53%)

, MAC

Macerich

$7.05 /

-0.3 (-4.08%)

, KR

Kroger

$33.17 /

-1.19 (-3.46%)

, KALA

Kala Pharmaceuticals

$8.01 /

-0.75 (-8.56%)

, MGM

MGM Resorts

$22.97 /

+0.25 (+1.10%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Jazz Pharmaceuticals (JAZZ) downgraded to Sell from Neutral at Goldman Sachs with analyst Graig Suvannavejh saying he sees the company's growth outlook as "challenged" and 6% downside risk in the shares. 2. Macerich (MAC) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Richard Hill saying he is shifting to an analysis of free cash flow as a better representation of the financial health of a company in the current environment of "rent deferral-driven deviations" in funds from operations for retail REITs. 3. Kroger (KR) downgraded to Neutral from Buy at BofA with analyst Robert Ohmes saying he has a more muted outlook for the company for the second half of FY21 and FY22 even though its multiple has been pushed out to 14-times expected earnings vs. 11-times average over the past two years. 4. Kala Pharmaceuticals (KALA) downgraded to Hold from Buy at Jefferies with analyst Biren Amin saying while he expects FDA approval for Eysuvis by its October 30 PDUFA date, the eye care professionals surveyed estimated Eysuvis could capture 12% market share at launch in year one and 13% in year two, assuming a price of $280/bottle. 5. MGM Resorts (MGM) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Grambling saying a slower recovery in Las Vegas will drive downside to consensus estimates and fundamental underperformance relative to peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

09/14/20 RBC Capital
Jazz Pharmaceuticals price target raised to $170 from $160 at RBC Capital
09/14/20 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
09/14/20 Goldman Sachs
Jazz Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
MAC Macerich
$7.05 /

-0.3 (-4.08%)

09/14/20 Morgan Stanley
Macerich downgraded to Underweight on downside risk at Morgan Stanley
09/14/20 Morgan Stanley
Macerich downgraded to Underweight from Equal Weight at Morgan Stanley
07/27/20 Deutsche Bank
Macerich price target lowered to $8 from $16 at Deutsche Bank
07/02/20 Citi
Macerich price target raised to $8 from $5 at Citi
KR Kroger
$33.17 /

-1.19 (-3.46%)

09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
09/14/20 BofA
Kroger downgraded to Neutral from Buy at BofA
08/06/20 Credit Suisse
Kroger assumed with a Neutral at Credit Suisse
07/30/20 MKM Partners
Kroger initiated with a Neutral at MKM Partners
KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
07/23/20
Fly Intel: Top five analyst initiations
MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

09/14/20 Goldman Sachs
MGM Resorts downgraded to Sell from Neutral at Goldman Sachs
09/09/20 JPMorgan
MGM Resorts price target raised to $23 from $17 at JPMorgan
08/19/20 Credit Suisse
IAC price target raised to $160 from $91.68 at Credit Suisse
08/18/20 BMO Capital
IAC price target raised to $174 from $171 at BMO Capital
MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

  • 11
    Mar
MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

JAZZ Jazz Pharmaceuticals
$139.02 /

+2.1 (+1.53%)

MGM MGM Resorts
$22.97 /

+0.25 (+1.10%)

MAC Macerich
$7.05 /

-0.3 (-4.08%)

KR Kroger
$33.17 /

-1.19 (-3.46%)

KALA Kala Pharmaceuticals
$8.01 /

-0.75 (-8.56%)

On The Fly
GameStop upgrades, MGM downgrade among today's top calls on Wall Street » 09:37
09/14/20
09/14
09:37
09/14/20
09:37
GME

GameStop

$6.09 /

-0.13 (-2.09%)

, MGM

MGM Resorts

$22.72 /

-0.1 (-0.44%)

, PENN

Penn National

$59.18 /

-3.22 (-5.16%)

, RRR

Red Rock Resorts

$17.15 /

-0.34 (-1.94%)

, OSTK

Overstock.com

$65.15 /

-9.2 (-12.37%)

, TMO

Thermo Fisher

$430.76 /

+11.31 (+2.70%)

, KALA

Kala Pharmaceuticals

$8.76 /

-0.16 (-1.79%)

Check out today's top…

ShowHide Related Items >><<
TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

RRR Red Rock Resorts
$17.15 /

-0.34 (-1.94%)

PENN Penn National
$59.18 /

-3.22 (-5.16%)

OSTK Overstock.com
$65.15 /

-9.2 (-12.37%)

MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

09/14/20 Jefferies
GameStop upgraded to Buy ahead of video game console cycle at Jefferies
09/14/20 Telsey Advisory
GameStop upgraded to Outperform from Market Perform at Telsey Advisory
09/14/20 Jefferies
GameStop upgraded to Buy from Hold at Jefferies
09/10/20 Baird
GameStop can still hit breakeven EBITDA this year, says Baird
MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

09/14/20 Goldman Sachs
MGM Resorts downgraded to Sell from Neutral at Goldman Sachs
09/09/20 JPMorgan
MGM Resorts price target raised to $23 from $17 at JPMorgan
08/19/20 Credit Suisse
IAC price target raised to $160 from $91.68 at Credit Suisse
08/18/20 BMO Capital
IAC price target raised to $174 from $171 at BMO Capital
PENN Penn National
$59.18 /

-3.22 (-5.16%)

09/14/20 Goldman Sachs
Penn National price target raised to $66 from $60 at Goldman Sachs
09/10/20
Fly Intel: Top five analyst initiations
09/09/20 Rosenblatt
Rosenblatt starts Penn National at Buy with 'Street high' $80 target
RRR Red Rock Resorts
$17.15 /

-0.34 (-1.94%)

09/14/20 Goldman Sachs
Red Rock Resorts price target raised to $20 from $15 at Goldman Sachs
09/09/20 JPMorgan
Red Rock Resorts price target raised to $21 from $17 at JPMorgan
09/02/20 Truist
Red Rock Resorts price target raised to $21 from $14 at Truist
OSTK Overstock.com
$65.15 /

-9.2 (-12.37%)

09/14/20 Needham
Overstock.com initiated with a Buy at Needham
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

09/14/20 Morgan Stanley
Thermo Fisher initiated with an Overweight at Morgan Stanley
09/11/20 Citi
Thermo Fisher price target raised to $485 from $471 at Citi
09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/24/20 Citi
Qiagen upgraded to Buy from Neutral at Citi
KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
07/23/20
Fly Intel: Top five analyst initiations
TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

RRR Red Rock Resorts
$17.15 /

-0.34 (-1.94%)

PENN Penn National
$59.18 /

-3.22 (-5.16%)

OSTK Overstock.com
$65.15 /

-9.2 (-12.37%)

MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

  • 12
    Aug
  • 12
    May
  • 11
    Mar
TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

PENN Penn National
$59.18 /

-3.22 (-5.16%)

MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

RRR Red Rock Resorts
$17.15 /

-0.34 (-1.94%)

PENN Penn National
$59.18 /

-3.22 (-5.16%)

OSTK Overstock.com
$65.15 /

-9.2 (-12.37%)

MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

TMO Thermo Fisher
$430.76 /

+11.31 (+2.70%)

RRR Red Rock Resorts
$17.15 /

-0.34 (-1.94%)

PENN Penn National
$59.18 /

-3.22 (-5.16%)

OSTK Overstock.com
$65.15 /

-9.2 (-12.37%)

MGM MGM Resorts
$22.72 /

-0.1 (-0.44%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

GME GameStop
$6.09 /

-0.13 (-2.09%)

Downgrade
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey » 06:54
09/14/20
09/14
06:54
09/14/20
06:54
KALA

Kala Pharmaceuticals

$8.76 /

-0.16 (-1.79%)

As previously reported,…

As previously reported, Jefferies analyst Biren Amin downgraded Kala Pharmaceuticals to Hold from Buy with a price target of $10, down from $21 after surveying 25 ophthalmologists and 25 optometrists who are based in the U.S. and treat an average of 224 dry eye disease patients per month. While Amin expects FDA approval for Eysuvis by its October 30 PDUFA date, the eye care professionals surveyed estimated Eysuvis could capture 12% market share at launch in year one and 13% in year two, assuming a price of $280/bottle, said Amin, who believes the company is evaluating a price in the range of $300-600/bottle. Most of the survey doctors pointed to product cost and insurance coverage as the main hurdle to strong Eysuvis adoption, added Amin.

ShowHide Related Items >><<
KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

  • 11
    Mar
KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

KALA Kala Pharmaceuticals
$8.76 /

-0.16 (-1.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.